Abrysvo is the first vaccine for the respiratory syncytial virus that is indicated for adults younger than 50, the drugmaker ...

Activist hedge fund Starboard Value's chief executive officer said on Tuesday that drugmaker Pfizer's board needs to hold ...

The U.S. Food and Drug Administration on Tuesday approved Pfizer's RSV vaccine for the prevention of lower respiratory tract ...

Abrysvo can prevent lower respiratory tract disease caused by RSV for people between the ages of 18 and 59 who are at ...

There's some rumbling going on within Pfizer's investment community, as an activist hedge fund says that the company's ...

An agency panel recommended lowering the age for routine vaccination from 65 to 50, boosting the revenue outlook for multiple ...

“These promising data add to the evidence supporting GSK’s RSV vaccine and could help expand protection to more adults at ...

With an expanded recommendation from the Center for Disease Control and Prevention (CDC)’s Advisory Committee on Immunization ...

Pfizer's focus should remain on existing cost realignment plans and pipeline investments. Read why my investment thesis ...

Activist investor Starboard met with Pfizer last week. Here's what went down, according to the hedge fund's cofounder and CEO ...

Starboard Value criticizes Pfizer's leadership for underperformance, citing a 50% stock decline and missed growth targets ...

The company has made it easier to test for different protein modifications which are critical to the treatment of autoimmune ...